Randomisation was performed using a permuted block design with a block size of 8 and exp:con ratios of 3:5, 4:4 or 5:3. Participants in the exercise group commenced the program when each block was completed, allowing supervised group exercise sessions comprising three to five women. Baseline measures were taken the day before the exercise program commenced and outcomes

were measured the day after the program was completed. The investigator responsible for randomly assigning participants Selleck Enzalutamide to treatment groups did not know in advance which treatment the next person would receive (concealed allocation) and did not participate in administering the intervention or measuring outcomes. The investigators responsible for assessing eligibility and baseline measures were blinded to group allocation. Participants and therapists administering the intervention were not blinded. The investigators responsible for outcome assessment were blinded to group allocation. All investigators received training before the trial and reminders during the trial regarding the protocol, measurement procedures, and methods and importance of maintaining blinding. Measurements were taken at baseline

(Month 0, which corresponded to between 16 and 20 weeks of gestation) and at the end of the three-month intervention period (Month 3, week 28–32 of gestation). Pregnant women this website were eligible for the study if they were aged between 16 and 30 years, between 16 and 20 weeks of gestation, with a live foetus at the routine ultrasound scan. They were excluded if they had participated in a structured

exercise program in the past six months or had a history of high blood pressure, chronic medical illnesses (cancer, renal, endocrinology, psychiatric, neurologic, infectious, and cardiovascular diseases), persistent bleeding after week 12 of gestation, poorly controlled thyroid disease, placenta praevia, incompetent cervix, polyhydramnios, oligohydramnios, miscarriage in the last twelve months, or diseases that could interfere with participation, according to the recommendations of the American College of Sports Medicine (ACSM 2000) and the American College of Obstetricians and Gynecologists (Artal and O’Toole Cediranib (AZD2171) 2003). At each participating centre two health professionals, who volunteered, were trained to recruit and assess eligibility. During the recruitment period, the opportunity to participate in the study was offered daily to all patients at the participating centres when they attended for routine antenatal care, if they previously had been identified on the doctors’ lists as being without a chronic pathology. The sessions were supervised by a physiotherapist and a physician. The participating centres were required to offer routine antenatal care and have facilities to allow the conduct of a supervised exercise class.